Dr. Chermansky received his medical training at Georgetown University in Washington DC. Dr. Chermansky completed his surgical internship and urology residency at the University of Texas Southwestern in Dallas under the chairmanship of both Dr. Paul C. Peters and Dr. John D. McConnell. After performing postgraduate research with Dr. Emil Tanagho in bladder tissue engineering at the University of California in San Francisco, he completed his fellowship in female urology and neurourology at the University of Pittsburgh with Dr. Michael B. Chancellor. Dr. Chermansky is board certified in FPMRS by the American Board of Urology. He is a member of the American Urological Association and the Society of Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction (SUFU). His practice is concentrated on the evaluation and treatment of voiding dysfunction in both women and men. He also treats patients with neurogenic bladder and female pelvic organ prolapse. An avid researcher, Dr. Chermansky has studied treatments for bladder overactivity and bladder pain. He has published in the area of stem cell therapy as treatment for female stress urinary incontinence. He is also an investigator in the use of Botulinum Toxin A for Overactive Bladder, Also, he is an investigator in the ROSETTA (Refractory Overactive Bladder: Sacral Neuromodulation versus Botulinum Toxin Assessment) Trial within NIH Pelvic Floor Disorders Network.
Dr Christopher John Chermansky declared on the Sunday 2nd April 2017 that they had the following existing or known future financial relationships or affiliations: